About: Cerebrospinal fluid amyloidβ peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: Indication of carrier-mediated epitope masking of amyloidβ peptides

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Cerebrospinal fluid amyloidβ peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: Indication of carrier-mediated epitope masking of amyloidβ peptides Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scholarly article by Mirko Bibl et al published September 2004 in Electrophoresis

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) article scientifique publié en 2004 (fr) наукова стаття, опублікована у вересні 2004 (uk) im September 2004 veröffentlichter wissenschaftlicher Artikel (de) scholarly article by Mirko Bibl et al published September 2004 in Electrophoresis (en)
publication date	wds:Q57780949-3BDF5208-E969-485C-B4FE-2B6A5F6A41C7
publication date	2004-09-01 00:00:00Z (xsd:dateTime)
author name string	wds:Q57780949-3266F513-A8C0-43C1-A4B3-F8BC8E7875E0 wds:Q57780949-C6123084-0054-466D-A270-F04913EB7265
author name string	Markus Otto Eckart Rüther
rdfs:label	Cerebrospinal fluid amyloidβ peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: Indication of carrier-mediated epitope masking of amyloidβ peptides (en) Cerebrospinal fluid amyloidβ peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: Indication of carrier-mediated epitope masking of amyloidβ peptides (nl)
skos:prefLabel	Cerebrospinal fluid amyloidβ peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: Indication of carrier-mediated epitope masking of amyloidβ peptides (en) Cerebrospinal fluid amyloidβ peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: Indication of carrier-mediated epitope masking of amyloidβ peptides (nl)
name	Cerebrospinal fluid amyloidβ peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: Indication of carrier-mediated epitope masking of amyloidβ peptides (en) Cerebrospinal fluid amyloidβ peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: Indication of carrier-mediated epitope masking of amyloidβ peptides (nl)
author	wds:Q57780949-3612B990-3E2F-4058-8108-EC50A9693463 wds:Q57780949-4163DC1C-9741-401E-ABC1-8BB47B9BA52A wds:Q57780949-4C0B10A1-C4D9-4BE6-AD80-E7A205BDFE75 wds:Q57780949-CC334A08-8FAC-4D3D-A9DA-82703A0D9ABC wds:Q57780949-E1503BA8-233D-4A00-95E3-0D7A0EAFE555 wds:Q57780949-EFC6ACB2-E00F-4466-A6F3-D76CDD6BD1BE
author	Johannes Kornhuber Mirko Bibl Piotr Lewczuk Hermann Esselmann Jens Wiltfang Lukas Cepek
title	wds:Q57780949-3313D2FB-4089-4EDA-9630-A0B8299443C7
title	Cerebrospinal fluid amyloidβ peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: Indication of carrier-mediated epitope masking of amyloidβ peptides (en)
page(s)	wds:Q57780949-CF29A337-B6C1-46E8-950C-A4E3019658DF
page(s)	2912-2918
instance of	wds:Q57780949-51437128-386F-4500-9F93-C7650ECE3B03
instance of	scholarly article
main subject	wds:Q57780949-B652DDF8-62E6-4B18-86E8-072C12E88261 wds:Q57780949-D137C2FD-274C-43DE-B3A0-61DC33DA4EFB
main subject	Alzheimer's disease Patients
PubMed ID	wds:Q57780949-714E7407-F941-4173-A1DA-7A4A6382CA9B
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/15349929
PubMed ID	15349929
published in	wds:Q57780949-D561695D-A998-416D-9026-3EA7250B61B6
published in	Electrophoresis
issue	wds:Q57780949-9A486D9F-5BC7-4310-8BE8-B3401D435E8F
volume	wds:Q57780949-5F28355E-BA72-44F9-82D3-37B79956A8D7
issue	17
volume	25
DOI	wds:Q57780949-5E777D16-8B7B-4EF4-8952-0B25345DF4E7
DOI	http://dx.doi.org/10.1002/ELPS.200305992
DOI	10.1002/ELPS.200305992
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q57780949
is cites work of	Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study. Characterization of cerebrospinal fluid aminoterminally truncated and oxidized amyloid-β peptides Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid Proteomic analysis of cerebrospinal fluid extracellular vesicles: a comprehensive dataset Cerebrospinal fluid and plasma biomarkers in Alzheimer disease A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. A facile method for expression and purification of the Alzheimer's disease-associated amyloid beta-peptide Cerebrospinal fluid amyloid-β 2-42 is decreased in Alzheimer's, but not in frontotemporal dementia The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: united we stand, divided we fall Cerebrospinal fluid neurochemical phenotypes in vascular dementias: original data and mini-review Clinical proteomics in neurodegenerative disorders Combined CSF tau, p-tau181 and amyloid-beta 38/40/42 for diagnosing Alzheimer's disease. Reduced CSF carboxyterminally truncated Aβ peptides in frontotemporal lobe degenerations Different CSF β-amyloid processing in Alzheimer’s and Creutzfeldt–Jakob disease Validation of amyloid-beta peptides in CSF diagnosis of neurodegenerative dementias. Tauopathies and synucleinopathies: Do cerebrospinal fluid β-amyloid peptides reflect disease-specific pathogenesis? Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update Quantification of α-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies CSF diagnosis of Alzheimer's disease and dementia with Lewy bodies. Consensus Guidelines for CSF and Blood Biobanking for CNS Biomarker Studies Targeted proteomics in Alzheimer's disease: focus on amyloid-beta HUPO Brain Proteome Project: aims and needs in proteomics Combined Analysis of CSF Tau, Aβ42, Aβ1-42% and Aβ1-40% in Alzheimer's Disease, Dementia with Lewy Bodies and Parkinson's Disease Dementia Mutational re-modeling of di-aspartyl intramembrane proteases: uncoupling physiologically-relevant activities from those associated with Alzheimer's disease. The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases Chromosome-centric approach to overcoming bottlenecks in the Human Proteome Project The impact of cerebrospinal fluid biomarkers on the diagnosis of Alzheimer's disease. Plasma Levels of Aβ42 and Tau Identified Probable Alzheimer's Dementia: Findings in Two Cohorts Biochemical premotor biomarkers for Parkinson's disease The HUPO Brain Proteome Project--no need to hurry? A consensus in Korea regarding a protocol to reduce preanalytical sources of variability in the measurement of the cerebrospinal fluid biomarkers of Alzheimer's disease. Cerebrospinal Fluid Aβ42/Aβ40 as a Means to Limiting Tube- and Storage-Dependent Pre-Analytical Variability in Clinical Setting. Stability of amyloid-β peptides in plasma and serum. Neurochemical biomarkers in Alzheimer's disease and related disorders. Biobanking of Cerebrospinal Fluid for Biomarker Analysis in Neurological Diseases How proteomics reveals potential biomarkers in brain diseases Soluble form of receptor for advanced glycation end-products (sRAGE): do sRAGE ligands or anti-sRAGE auto-antibodies interfere with sRAGE quantification? Plasma amyloid-beta peptides in acute cerebral ischemia: a pilot study. Selective reduction of amyloid beta42 discriminates Alzheimer's disease from Huntington's disease: indication for distinct pathological events in amyloid beta peptide aggregation Konsensusprotokoll zur Standardisierung von Entnahme und Biobanking des Liquor cerebrospinalis 1 / A consensus protocol for the standardisation of cerebrospinal fluid collection and biobanking
is cites work of	wds:Q34244772-CA908CF1-6F6C-4FCA-8D32-1A6E5E3AA8B3 wds:Q24295851-435F7067-2FD0-4CA8-AC9D-F2F556C72580 wds:Q34078408-88E0A770-CDB7-47F6-8BEA-824E7D9E797F wds:Q47155049-A37CC812-518C-480C-AB13-202B65198E5A wds:Q36162523-A88D52E3-EDF2-44C4-850A-2F9666C27AE8

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 193 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software